Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Feb 14, 2023
- Accession no.
- 0001447362-23-000017
- Filed
- Feb 14, 2023
- Trade date
- Feb 10-13, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 14 non-derivative transactions. Open-market sales total $219.2K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2023 | Common Stock | SSaleDisposed | −2,489 | $26.17F2 | −$65,137.13 | 166,244 | Direct | |
| Feb 10, 2023 | Common Stock | SSaleDisposed | −1,244 | $26.17F2 | −$32,555.48 | 120,686 | Indirect | |
| Feb 10, 2023 | Common Stock | SSaleDisposed | −1,244 | $26.17F2 | −$32,555.48 | 109,581 | Indirect | |
| Feb 10, 2023 | Common Stock | SSaleDisposed | −621 | $26.17F2 | −$16,251.57 | 23,778 | Indirect | |
| Feb 10, 2023 | Common Stock | SSaleDisposed | −621 | $26.17F2 | −$16,251.57 | 23,780 | Indirect | |
| Feb 10, 2023 | Common Stock | SSaleDisposed | −622 | $26.17F2 | −$16,277.74 | 23,779 | Indirect | |
| Feb 10, 2023 | Common Stock | SSaleDisposed | −621 | $26.17F2 | −$16,251.57 | 23,772 | Indirect | |
| Feb 13, 2023 | Common Stock | SSaleDisposed | −303 | $26.26F9 | −$7,956.78 | 165,941 | Direct | |
| Feb 13, 2023 | Common Stock | SSaleDisposed | −152 | $26.26F9 | −$3,991.52 | 120,534 | Indirect | |
| Feb 13, 2023 | Common Stock | SSaleDisposed | −152 | $26.26F9 | −$3,991.52 | 109,429 | Indirect | |
| Feb 13, 2023 | Common Stock | SSaleDisposed | −75 | $26.26F9 | −$1,969.5 | 23,703 | Indirect | |
| Feb 13, 2023 | Common Stock | SSaleDisposed | −76 | $26.26F9 | −$1,995.76 | 23,704 | Indirect | |
| Feb 13, 2023 | Common Stock | SSaleDisposed | −76 | $26.26F9 | −$1,995.76 | 23,703 | Indirect | |
| Feb 13, 2023 | Common Stock | SSaleDisposed | −76 | $26.26F9 | −$1,995.76 | 23,696 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $25.880 to $26.515, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $25.785 to $26.465, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.